$PIRS
PIERIS PHARMACEUTICALS, INC.

2017 Q2 Form 10-Q Financial Statement

#000119312517170782 Filed on May 15, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2017 Q1 2016 Q1
Revenue $1.853M $1.343M $1.247M
YoY Change 72.72% 7.73% 472.85%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.350M $3.990M $1.970M
YoY Change 83.54% 102.54% -17.57%
% of Gross Profit
Research & Development $5.396M $5.360M $3.659M
YoY Change 19.91% 46.47% 140.02%
% of Gross Profit
Depreciation & Amortization $110.0K $100.0K $94.52K
YoY Change -1200.0% 5.8% 21.0%
% of Gross Profit
Operating Expenses $9.744M $9.349M $5.627M
YoY Change 41.87% 66.14% 43.59%
Operating Profit -$7.891M -$8.006M -$4.381M
YoY Change 36.16% 82.76% 18.35%
Interest Expense $0.00 $0.00 $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net -$1.380M $12.00K $219.6K
YoY Change 1471.74% -94.54% 28459.17%
Pretax Income -$9.271M -$7.994M -$4.161M
YoY Change 57.58% 92.11% 12.32%
Income Tax $814.0K $0.00 $0.00
% Of Pretax Income
Net Earnings -$10.09M -$7.994M -$4.161M
YoY Change 71.42% 92.11% 12.32%
Net Earnings / Revenue -544.25% -595.23% -333.78%
Basic Earnings Per Share
Diluted Earnings Per Share -$232.2K -$185.6K -$104.4K
COMMON SHARES
Basic Shares Outstanding 43.07M shares 43.06M shares 39.83M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q2 2017 Q1 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $50.30M $55.20M $31.20M
YoY Change 24.5% 76.92% 136.36%
Cash & Equivalents $50.32M $55.24M $31.19M
Short-Term Investments
Other Short-Term Assets $3.900M $3.500M $3.600M
YoY Change 11.43% -2.78% 182.19%
Inventory
Prepaid Expenses
Receivables $48.47M $39.01K $70.26K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $102.7M $58.76M $34.87M
YoY Change 134.14% 68.52% 132.98%
LONG-TERM ASSETS
Property, Plant & Equipment $3.085M $2.993M $2.210M
YoY Change 26.08% 35.41% 23.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $128.2K $126.2K $128.0K
YoY Change 0.69% -1.43%
Total Long-Term Assets $3.213M $3.119M $2.338M
YoY Change 24.82% 33.39% 29.24%
TOTAL ASSETS
Total Short-Term Assets $102.7M $58.76M $34.87M
Total Long-Term Assets $3.213M $3.119M $2.338M
Total Assets $106.0M $61.88M $37.21M
YoY Change 128.09% 66.31% 121.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.646M $3.317M $1.700M
YoY Change 190.39% 95.12% 13.33%
Accrued Expenses $6.351M $2.959M $2.322M
YoY Change 173.11% 27.43% 461.7%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $35.80M $11.44M $6.498M
YoY Change 457.62% 76.13% 188.68%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $42.86K $42.09K $39.74K
YoY Change 1.9% 5.9% -86.75%
Total Long-Term Liabilities $42.86K $42.09K $39.74K
YoY Change 1.9% 5.9% -86.75%
TOTAL LIABILITIES
Total Short-Term Liabilities $35.80M $11.44M $6.498M
Total Long-Term Liabilities $42.86K $42.09K $39.74K
Total Liabilities $96.62M $43.84M $10.03M
YoY Change 954.49% 337.12% 293.71%
SHAREHOLDERS EQUITY
Retained Earnings -$120.7M -$110.7M -$84.03M
YoY Change 34.29% 31.69% 20.88%
Common Stock $132.2M $130.1M $112.6M
YoY Change 2.83% 15.55% 382621.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.334M $18.04M $27.18M
YoY Change
Total Liabilities & Shareholders Equity $106.0M $61.88M $37.21M
YoY Change 128.09% 66.31% 121.79%

Cashflow Statement

Concept 2017 Q2 2017 Q1 2016 Q1
OPERATING ACTIVITIES
Net Income -$10.09M -$7.994M -$4.161M
YoY Change 71.42% 92.11% 12.32%
Depreciation, Depletion And Amortization $110.0K $100.0K $94.52K
YoY Change -1200.0% 5.8% 21.0%
Cash From Operating Activities -$6.520M $25.77M $2.030M
YoY Change 6.71% 1169.46% -154.57%
INVESTING ACTIVITIES
Capital Expenditures -$670.0K $179.0K $67.92K
YoY Change 1240.0% 163.55% 67.09%
Acquisitions
YoY Change
Other Investing Activities $10.00K
YoY Change
Cash From Investing Activities -$660.0K -$180.0K -$70.00K
YoY Change 1220.0% 157.14% 75.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.460M 0.000 0.000
YoY Change -90.45% -100.0%
NET CHANGE
Cash From Operating Activities -6.520M 25.77M 2.030M
Cash From Investing Activities -660.0K -180.0K -70.00K
Cash From Financing Activities 1.460M 0.000 0.000
Net Change In Cash -5.720M 25.59M 1.960M
YoY Change -162.72% 1205.61% -141.18%
FREE CASH FLOW
Cash From Operating Activities -$6.520M $25.77M $2.030M
Capital Expenditures -$670.0K $179.0K $67.92K
Free Cash Flow -$5.850M $25.59M $1.962M
YoY Change -3.47% 1204.28% -152.17%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43068790 shares
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31188527
CY2017Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
844786
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q1 us-gaap Cash
Cash
55241957
CY2017Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43058827 shares
CY2017Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43058827 shares
CY2017Q1 us-gaap Assets
Assets
61875181
CY2017Q1 us-gaap Assets Current
AssetsCurrent
58755983
CY2017Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2017Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
130101961
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
55241957
CY2017Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
39013
CY2017Q1 us-gaap Common Stock Value
CommonStockValue
43059
CY2017Q1 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
0
CY2017Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
32352662
CY2017Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3317122
CY2017Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
5168614
CY2017Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
782203
CY2017Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1450617
CY2017Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2958877
CY2017Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
4963 shares
CY2017Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
4963 shares
CY2017Q1 us-gaap Liabilities
Liabilities
43839361
CY2017Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
61875181
CY2017Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
42086
CY2017Q1 us-gaap Liabilities Current
LiabilitiesCurrent
11444613
CY2017Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
179767
CY2017Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
126193
CY2017Q1 us-gaap Preferred Stock Value
PreferredStockValue
5
CY2017Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2993005
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
18035820
CY2017Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110658588
CY2017Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3475013
CY2017Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
4963 shares
CY2017Q1 pirs Accrued Tax Audit And Legal Fees
AccruedTaxAuditAndLegalFees
374548
CY2017Q1 pirs Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
2958877
CY2017Q1 pirs Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
777573
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29349124
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1198448
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Cash
Cash
29355528
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43058827 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43058827 shares
CY2016Q4 us-gaap Assets
Assets
35062831
CY2016Q4 us-gaap Assets Current
AssetsCurrent
32672613
CY2016Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
129349768
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29355528
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
57582
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
43059
CY2016Q4 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
0
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1409483
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2386183
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2274514
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
867969
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1501452
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3719457
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
4963 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
4963 shares
CY2016Q4 us-gaap Liabilities
Liabilities
9836304
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
35062831
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
46667
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8380154
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
157788
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
125741
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
5
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2264477
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
25226527
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-102664853
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3259503
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
4963 shares
CY2016Q4 pirs Accrued Tax Audit And Legal Fees
AccruedTaxAuditAndLegalFees
454931
CY2016Q4 pirs Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
3719457
CY2016Q4 pirs Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
1040321
CY2017Q1 dei Entity Registrant Name
EntityRegistrantName
PIERIS PHARMACEUTICALS, INC.
CY2017Q1 dei Document Type
DocumentType
10-Q
CY2017Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001583648
CY2017Q1 dei Document Period End Date
DocumentPeriodEndDate
2017-03-31
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
25886429
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
752193
CY2017Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017Q1 dei Amendment Flag
AmendmentFlag
false
CY2017Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3988880
CY2017Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
294934
CY2017Q1 us-gaap Depreciation
Depreciation
100348
CY2017Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7942901
CY2017Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2017Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
100
CY2017Q1 us-gaap Revenues
Revenues
1343300
CY2017Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
11701
CY2017Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
263025
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-805903
CY2017Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
50834
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
9348836
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-7993735
CY2017Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7993735
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-179066
CY2017Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-19328
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
81149
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8005536
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
0
CY2017Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
50834
CY2017Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
33516454
CY2017Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
25770561
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
179066
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0216 pure
CY2017Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2017Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of the condensed consolidated financial statements in accordance with U.S. GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities, the reported amounts of revenues, and expenses in the financial statements and disclosures in the accompanying notes. Significant estimates are used for, but are not limited to, revenue recognition, deferred tax assets, liabilities and valuation allowances, fair value of stock options and various accruals. Management evaluates its estimates on an ongoing basis. Actual results and outcomes could differ materially from management&#x2019;s estimates, judgments and assumptions.</p> </div>
CY2017Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
0
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7513 pure
CY2017Q1 us-gaap Revenue Recognition Milestone Method Milestone
RevenueRecognitionMilestoneMethodMilestone
Pieris aggregates milestones into four categories (i) research milestones, (ii) development milestones, (iii) commercial milestones and (iv) sales milestones.
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
1.31
CY2016Q1 us-gaap Depreciation
Depreciation
94521
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4324394
CY2016Q1 us-gaap Revenues
Revenues
1246644
CY2016Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
219620
CY2016Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
368383
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1967883
CY2016Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-119236
CY2017Q1 dei Trading Symbol
TradingSymbol
PIRS
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5359956
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0204 pure
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
752193
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7509 pure
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43063790 shares
CY2017Q1 pirs Property And Equipment Included In Accounts Payable
PropertyAndEquipmentIncludedInAccountsPayable
613406
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1839403
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2016Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
597189
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
543037
CY2016Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-163340
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
5627318
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-4161054
CY2016Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4161054
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-67919
CY2016Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
68870
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1185384
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4380674
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
0
CY2016Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-163340
CY2016Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
5838737
CY2016Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
2026559
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
67919
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0161 pure
CY2016Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7600 pure
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
1.00
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3659435
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0135 pure
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
368383
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7553 pure
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39833023 shares

Files In Submission

Name View Source Status
0001193125-17-170782-index-headers.html Edgar Link pending
0001193125-17-170782-index.html Edgar Link pending
0001193125-17-170782.txt Edgar Link pending
0001193125-17-170782-xbrl.zip Edgar Link pending
d373026d10q.htm Edgar Link pending
d373026dex103.htm Edgar Link pending
d373026dex311.htm Edgar Link pending
d373026dex312.htm Edgar Link pending
d373026dex321.htm Edgar Link pending
d373026dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
pirs-20170331.xml Edgar Link completed
pirs-20170331.xsd Edgar Link pending
pirs-20170331_cal.xml Edgar Link unprocessable
pirs-20170331_def.xml Edgar Link unprocessable
pirs-20170331_lab.xml Edgar Link unprocessable
pirs-20170331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending